Drug intelligence / Profile preview

AR2001

Development stage: Discontinued
Lead developer: AriBio
Modality: Small Molecules
Administration: Oral

Overview

AR2001 is an investigational **small-molecule** drug candidate developed by **AriBio** for **sepsis** and **COVID-19**. Publicly available pipeline sources identify it only at a high level as a **GPCR agonist**, but do not clearly disclose the exact molecular target, receptor subtype, or detailed pharmacology. Available evidence suggests it was an early-stage infectious disease and critical care program that remained **preclinical** and was later **discontinued/terminated**, with no evidence of regulatory approval or marketed status.

Beyond the preview

Go deeper on AR2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR2001.

Explore the full profile